Covered recipient · General Payments record
TAMAR F BRIONEZ
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$23,602.46
153 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,800.00 | 9 |
| Food and Beverage | $2,379.73 | 141 |
| Honoraria | $1,475.00 | 1 |
| Consulting Fee | $900.00 | 1 |
| Travel and Lodging | $47.73 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $13,573.30 | 10 |
| AbbVie Inc. | $3,382.67 | 19 |
| UCB, Inc. | $3,357.37 | 12 |
| Horizon Therapeutics plc | $1,516.14 | 4 |
| Amgen Inc. | $475.15 | 30 |
| Mallinckrodt Hospital Products Inc. | $288.03 | 15 |
| PFIZER INC. | $249.89 | 19 |
| Novartis Pharmaceuticals Corporation | $153.38 | 8 |
| Lilly USA, LLC | $123.24 | 8 |
| Janssen Biotech, Inc. | $95.06 | 8 |
| Radius Health, Inc. | $77.24 | 5 |
| Janssen Scientific Affairs, LLC | $58.18 | 2 |
| GENZYME CORPORATION | $56.72 | 3 |
| E.R. Squibb & Sons, L.L.C. | $47.79 | 3 |
| Gilead Sciences, Inc. | $35.89 | 1 |
| Teva Pharmaceuticals USA, Inc. | $26.97 | 1 |
| SANOFI-AVENTIS U.S. LLC | $21.56 | 1 |
| Hikma Pharmaceuticals USA | $20.92 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.42 | 1 |
| SOBI, INC | $14.29 | 1 |
| Antares Pharma, Inc. | $13.25 | 1 |
Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TAMAR F BRIONEZ
NPI 1457407041 · CMS profile ID 20898
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
THE WOODLANDS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457407041?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457407041?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457407041?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 153 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457407041?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
153 matching records · $23,602.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 153.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $16.26 | 04/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329235 | CMS |
| Mallinckrodt Hospital Products Inc. | $17.31 | 04/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691205 | CMS |
| Amgen Inc. | $17.44 | 04/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329249 | CMS |
| Mallinckrodt Hospital Products Inc. | $24.94 | 03/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691203 | CMS |
| AbbVie Inc. | $1,000.00 | 03/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708827 | CMS |
| AbbVie Inc. | $47.73 | 03/11/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708825 | CMS |
| Janssen Scientific Affairs, LLC | $36.67 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719445985 | CMS |
| Novartis Pharmaceuticals Corporation | $18.26 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725603601 | CMS |
| PFIZER INC. | $8.53 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743129421 | CMS |
| GENZYME CORPORATION | $18.80 | 03/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744262569 | CMS |
| GlaxoSmithKline, LLC. | $1,500.00 | 03/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738863869 | CMS |
| PFIZER INC. | $10.55 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743141669 | CMS |
| PFIZER INC. | $9.31 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743141407 | CMS |
| Amgen Inc. | $15.38 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329213 | CMS |
| Amgen Inc. | $13.42 | 03/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329233 | CMS |
| AbbVie Inc. | $24.64 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708823 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727788781 | CMS |
| AbbVie Inc. | $21.19 | 02/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708821 | CMS |
| AbbVie Inc. | $2,000.00 | 02/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708819 | CMS |
| AbbVie Inc. | $21.05 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708817 | CMS |
| Amgen Inc. | $18.62 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329247 | CMS |
| Mallinckrodt Hospital Products Inc. | $3.44 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691199 | CMS |
| Mallinckrodt Hospital Products Inc. | $21.26 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691201 | CMS |
| PFIZER INC. | $16.05 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743120286 | CMS |
| PFIZER INC. | $3.83 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743129419 | CMS |
| Novartis Pharmaceuticals Corporation | $22.70 | 02/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725603609 | CMS |
| Janssen Biotech, Inc. | $16.22 | 02/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719445981 | CMS |
| UCB, Inc. | $36.92 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746075075 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.42 | 02/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721007279 | CMS |
| Radius Health, Inc. | $17.22 | 02/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746267601 | CMS |
| Novartis Pharmaceuticals Corporation | $7.50 | 02/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725603577 | CMS |
| Novartis Pharmaceuticals Corporation | $17.95 | 02/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725603585 | CMS |
| Lilly USA, LLC | $16.22 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728675703 | CMS |
| Mallinckrodt Hospital Products Inc. | $28.38 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691197 | CMS |
| Amgen Inc. | $14.03 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329211 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.91 | 01/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727788777 | CMS |
| Gilead Sciences, Inc. | $35.89 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747956361 | CMS |
| Amgen Inc. | $33.36 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329245 | CMS |
| Mallinckrodt Hospital Products Inc. | $24.09 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751691195 | CMS |
| Novartis Pharmaceuticals Corporation | $22.18 | 01/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725603593 | CMS |
| PFIZER INC. | $3.81 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743129407 | CMS |
| PFIZER INC. | $6.55 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743129411 | CMS |
| PFIZER INC. | $6.18 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743129441 | CMS |
| PFIZER INC. | $14.70 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743066759 | CMS |
| GlaxoSmithKline, LLC. | $14.69 | 01/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738657279 | CMS |
| Lilly USA, LLC | $6.90 | 01/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728675701 | CMS |
| Amgen Inc. | $14.25 | 01/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741447115 | CMS |
| AbbVie Inc. | $20.32 | 01/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721708815 | CMS |
| Amgen Inc. | $8.19 | 01/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741329231 | CMS |
| Janssen Biotech, Inc. | $16.31 | 01/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719445983 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,217,311.76 | 78 |
| PY2024 | Recipient | $36,664.58 | 2 |
| PY2024 | Principal investigator | $1,040,077.60 | 67 |
| PY2023 | Principal investigator | $583,130.23 | 92 |
| PY2022 | Principal investigator | $859,473.48 | 257 |
| PY2021 | Principal investigator | $616,368.11 | 128 |
| PY2020 | Recipient | $2,603.72 | 4 |
| PY2020 | Principal investigator | $574,505.51 | 143 |
| PY2019 | Recipient | $13,017.22 | 5 |
| PY2019 | Principal investigator | $143,696.84 | 23 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
78 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $6,530.00 | 12/22/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418777 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,765.27 | 12/19/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223290032 |
| Principal investigator 1 | Amgen Inc. | $150.00 | 12/05/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246639177 |
| Principal investigator 1 | ABBVIE INC. | $6,071.24 | 12/04/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202528702 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.00 | 12/01/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190303591 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,567.27 | 12/01/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223289124 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17.12 | 11/15/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190303585 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 11/05/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202522407 |
| Principal investigator 1 | ABBVIE INC. | $2,203.38 | 11/04/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202520681 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,186.00 | 10/31/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418822 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 10/28/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202518837 |
| Principal investigator 1 | ABBVIE INC. | $36.92 | 10/24/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202518495 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,937.27 | 10/15/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223287001 |
| Principal investigator 1 | ABBVIE INC. | $2,094.58 | 10/09/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202516207 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $436.93 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190303595 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $493.37 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190303599 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,700.00 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286515 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286517 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286519 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 10/07/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202513469 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $550.00 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286329 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286331 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,024.62 | 10/01/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223286155 |
| Principal investigator 1 | Eli Lilly and Company | $111.45 | 09/09/2025 | Non-covered Recipient Entity TAMAR BRIONEZ | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187892322 |
| Principal investigator 1 | ABBVIE INC. | $4,893.59 | 09/03/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202507537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,282.00 | 09/01/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418802 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,368.94 | 08/20/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY PC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223284389 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $29,137.95 | 08/15/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225336029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,395.00 | 08/11/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418766 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 08/07/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202503897 |
| Principal investigator 1 | ABBVIE INC. | $1,188.70 | 08/05/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202501750 |
| Principal investigator 1 | ABBVIE INC. | $2,226.99 | 08/01/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202500830 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,000.00 | 07/23/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY PC | A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 | No dispute reported | 06/30/2026 | 1223283010 |
| Principal investigator 1 | Amgen Inc. | $32,363.77 | 07/16/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246638871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,230.00 | 07/07/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418756 |
| Principal investigator 1 | ABBVIE INC. | $4,338.46 | 07/02/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202494237 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494361 |
| Principal investigator 1 | ABBVIE INC. | $1,162.96 | 07/02/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202494363 |
| Principal investigator 1 | ABBVIE INC. | $50.11 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494365 |
| Principal investigator 1 | ABBVIE INC. | $25.60 | 07/02/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202494367 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $75.00 | 06/26/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | No dispute reported | 06/30/2026 | 1192115379 |
| Principal investigator 1 | Amgen Inc. | $139,782.10 | 06/04/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639179 |
| Principal investigator 1 | ABBVIE INC. | $2,042.73 | 06/03/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202489571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,282.00 | 06/02/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418796 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 05/29/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202487101 |
| Principal investigator 1 | Eli Lilly and Company | $13,437.00 | 05/27/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187876885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 05/23/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418790 |
| Principal investigator 1 | ABBVIE INC. | $2,256.06 | 05/06/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202482279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,186.00 | 04/28/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418782 |
| Principal investigator 1 | ABBVIE INC. | $3,131.40 | 04/03/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202471152 |
| Principal investigator 1 | ABBVIE INC. | $24.06 | 04/03/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202471156 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,372.00 | 03/31/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418772 |
| Principal investigator 1 | ABBVIE INC. | $4,666.81 | 03/06/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202456940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $82.00 | 02/17/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418761 |
| Principal investigator 1 | Amgen Inc. | $16,867.23 | 02/11/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246638875 |
| Principal investigator 1 | ABBVIE INC. | $18.58 | 02/06/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202447082 |
| Principal investigator 1 | ABBVIE INC. | $2,589.93 | 02/05/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202443927 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,334.90 | 01/30/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190311283 |
| Principal investigator 1 | ABBVIE INC. | $34.51 | 01/29/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202441763 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,092.00 | 01/28/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190311273 |
| Principal investigator 1 | Eli Lilly and Company | $3,156.90 | 01/27/2025 | Non-covered Recipient Entity TAMAR BRIONEZ | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187889648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,476.00 | 01/27/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418808 |
| Principal investigator 1 | Amgen Inc. | $42,018.44 | 01/22/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246638873 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $83,021.41 | 01/21/2025 | Non-covered Recipient Entity Advanced Rheumatology Of Houston | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) | No dispute reported | 06/30/2026 | 1235999277 |
| Principal investigator 1 | Janssen Research & Development, LLC | $82.00 | 01/20/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175418815 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,629.75 | 01/16/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) | No dispute reported | 06/30/2026 | 1190311275 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $148,097.15 | 01/16/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190311279 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,795.00 | 01/16/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190311281 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,408.00 | 01/14/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190311277 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $75.00 | 01/10/2025 | Non-covered Recipient Entity TAMAR BRIONEZ MD PA | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | No dispute reported | 06/30/2026 | 1192115373 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $54,864.08 | 01/09/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190303597 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,373.44 | 01/09/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190303601 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,108.43 | 01/09/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190303603 |
| Principal investigator 1 | Eli Lilly and Company | $146,650.00 | 01/07/2025 | Non-covered Recipient Entity ARH RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187880723 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,283.52 | 01/07/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190303587 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $244,129.76 | 01/06/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) | No dispute reported | 06/30/2026 | 1190303589 |
| Principal investigator 1 | ABBVIE INC. | $3,323.94 | 01/02/2025 | Non-covered Recipient Entity DR TAMAR F BRIONEZ MD PA | M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | No dispute reported | 06/30/2026 | 1202433626 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,835.14 | 01/01/2025 | Non-covered Recipient Entity ADVANCED RHEUMATOLOGY OF HOUSTON | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien | No dispute reported | 06/30/2026 | 1190303593 |